Thrivent Financial for Lutherans Has $1.44 Million Stake in Inspire Medical Systems, Inc. $INSP

Thrivent Financial for Lutherans trimmed its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 82.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,415 shares of the company’s stock after selling 91,253 shares during the period. Thrivent Financial for Lutherans owned approximately 0.07% of Inspire Medical Systems worth $1,441,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Royal Bank of Canada lifted its stake in Inspire Medical Systems by 16.0% in the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after acquiring an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Inspire Medical Systems in the first quarter valued at approximately $524,000. Goldman Sachs Group Inc. lifted its position in shares of Inspire Medical Systems by 57.9% in the first quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after purchasing an additional 18,857 shares in the last quarter. KLP Kapitalforvaltning AS lifted its position in shares of Inspire Medical Systems by 10.5% in the second quarter. KLP Kapitalforvaltning AS now owns 6,300 shares of the company’s stock worth $818,000 after purchasing an additional 600 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its holdings in Inspire Medical Systems by 29.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 2,360 shares of the company’s stock worth $306,000 after purchasing an additional 538 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on INSP shares. Wolfe Research lowered shares of Inspire Medical Systems from an “outperform” rating to a “peer perform” rating in a research note on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, December 29th. Royal Bank Of Canada dropped their target price on Inspire Medical Systems from $90.00 to $68.00 and set a “sector perform” rating on the stock in a report on Thursday. Truist Financial reduced their price target on Inspire Medical Systems from $96.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday. Finally, UBS Group set a $67.00 price target on Inspire Medical Systems in a research note on Friday. Five research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Inspire Medical Systems currently has a consensus rating of “Hold” and a consensus target price of $108.94.

Key Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: INSP reported $1.65 EPS vs. $0.69 expected and revenue of ~$269M, with expanded gross margins — a near-term operational positive. Zacks: INSP Beats Q4 Estimates
• Positive Sentiment: Some firms remain constructive at reduced targets — Mizuho and Piper Sandler kept outperform/overweight stances after lowering PTs, signaling there’s still perceived upside if reimbursement issues resolve. The Fly: Mizuho PT Cut
• Neutral Sentiment: Earnings call materials and transcript are available for detailed read-through (management commentary on coding, reimbursement and 2026 guide are key). Review to judge whether guidance risks are transitory. Seeking Alpha: Q4 Earnings Call Transcript
• Negative Sentiment: Management issued a 2026 revenue outlook of $950M–$1B and flagged a coding change plus reimbursement headwinds — the primary catalyst for the selloff risk and weaker forward expectations. MSN: 2026 Revenue Outlook & Coding Change
• Negative Sentiment: Multiple analyst downgrades and price-target cuts (Wells Fargo, Baird, Jefferies, Truist and others) followed the guidance and reimbursement concerns, increasing near-term selling pressure. Investing.com: Baird, Wells Fargo Cuts
• Negative Sentiment: The stock already experienced an earlier ~8% intraday decline after the coding/guidance news, showing how sensitive the market is to reimbursement updates. Investing.com: Shares Slide 8%

Insiders Place Their Bets

In related news, Director Shawn Mccormick sold 2,000 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.48, for a total value of $254,960.00. Following the sale, the director owned 26,046 shares in the company, valued at approximately $3,320,344.08. This represents a 7.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.10% of the company’s stock.

Inspire Medical Systems Stock Performance

Shares of NYSE:INSP opened at $59.78 on Friday. Inspire Medical Systems, Inc. has a 52-week low of $53.11 and a 52-week high of $197.75. The company has a market capitalization of $1.74 billion, a P/E ratio of 12.00, a price-to-earnings-growth ratio of 6.34 and a beta of 0.74. The company has a 50-day simple moving average of $92.88 and a 200 day simple moving average of $90.99.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.69 by $0.96. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm had revenue of $269.08 million for the quarter, compared to analyst estimates of $264.02 million. During the same quarter in the prior year, the company earned $1.15 earnings per share. The business’s revenue for the quarter was up 12.2% compared to the same quarter last year. As a group, equities analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.